10.80
+5.78%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Design Therapeutics
From its filings with the US Securities and Exchange Commission
Design Therapeutics is based in Carlsbad, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DSGN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $69.8m. At that date it held total assets of $226.2m and shareholders' equity of $212.5m.
We are a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC® molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Certain diseases caused by inherited nucleotide repeat expansion, such as Friedreich ataxia (FA) and fragile X syndrome, can result in reduced gene expression and deficiency of vital proteins; in other diseases, such as myotonic dystrophy type-1 (DM1), Fuchs endothelial corneal dystrophy (FECD), and Huntington's disease (HD), the nucleotide repeat expansions result in the generation of toxic gene products, often associated with pathological nuclear foci and broad splicing disruptions or the expression of mutant proteins that form toxic aggregates. Our GeneTAC® small molecules are designed to selectively target expanded genetic repeat sequences, modulate gene expression either by dialing up or down mRNA transcription, depending on the cause of the disease, and restore cellular health. As a platform, we believe that GeneTAC® molecules have broad potential applicability across currently unaddressed degenerative, monogenic nucleotide repeat expansion diseases affecting millions of individuals worldwide.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Mar 2021
- Employees
- 54
- Website
- designtx.com ↗
- Head office
- 6005 HIDDEN VALLEY ROAD, CARLSBAD, CA, 92011
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Dr. Pratik ShahChairman of the Board, President, Chief Executive Officer, Principal Financial Officer, since 2017$789,800
- Dr. Sean JeffriesChief Operating Officer$1.3m
- Dr. Christopher StorgardChief Medical Officer
- Dr. Simeon GeorgeLead Independent Director$137,980
- Mr. Justin GoverDirector
- Dr. Heather BergerIndependent Director$105,105
- Dr. Rodney LappeIndependent Director$116,980
- Mr. John SchmidIndependent Director$117,980
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 41
- Environment
- 40
- Social
- 71
- Governance
- 12
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Design Therapeutics Inc focuses on GeneTAC molecules for degenerative disorders in Health Care sector.
- The company's lead product candidate Friedreich ataxia (FA) addresses a serious monogenic disease.
- Design Therapeutics employs 57 full-time employees in Carlsbad, California for R&D.
Weaknesses
- The company has only two product candidates: Friedreich ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD).
- Design Therapeutics Inc has a small workforce of 57 employees in Carlsbad.
- The company's IPO was on 26 March 2021, indicating limited market history.
Opportunities
- GeneTAC program expansion to address other nucleotide repeat-driven monogenic diseases.
- Potential market for Friedreich ataxia (FA) treatment in the US Health Care sector.
- Advancement of Myotonic Dystrophy Type-1 (DM1) program in the Biotechnology industry.
Threats
- Competition from other biotechnology firms in the Health Care sector.
- Regulatory challenges for gene-targeted therapies in the US market.
- High R&D costs for developing novel therapies like GeneTAC molecules.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.